- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma ; volume:25 ; number:10 ; day:9 ; month:9 ; year:2023 ; pages:1191-1201 ; date:10.2023
Current oncology reports ; 25, Heft 10 (9.9.2023), 1191-1201, 10.2023
- Urheber
-
Crook, Christiana J.
Li, Daneng
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11912-023-01455-9
- URN
-
urn:nbn:de:101:1-2023122722582781400566
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Crook, Christiana J.
- Li, Daneng
- SpringerLink (Online service)
Ähnliche Objekte (12)
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial
Analysis of early postoperative complications in patients with resectable rectal cancer after neo-adjuvant chemo-radiotherapy
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial
Analysis of early postoperative complications in patients with resectable rectal cancer after neo-adjuvant chemo-radiotherapy
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial
Analysis of early postoperative complications in patients with resectable rectal cancer after neo-adjuvant chemo-radiotherapy
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)